BullFrog AI Holdings has entered a commercial agreement with a top 5 global pharmaceutical company to apply its AI-driven drug discovery platform to identify and prioritise a therapeutic target in Major Depressive Disorder, marking a further step in the company’s push into large-scale pharma collaborations.

The agreement will use BullFrog AI’s end-to-end analytical platform to support target identification and prioritisation within a major depressive disorder programme, with the aim of accelerating early-stage drug discovery and downstream development activities. The collaboration also includes exclusive access to a target candidate identified through the process.

The company said the partnership represents external validation of its causal AI approach to complex biological data analysis, as pharmaceutical companies continue to look for new methods to improve success rates in drug discovery.

BullFrog AI founder and chief executive Vin Singh said the agreement reflects strong industry confidence in the platform and highlighted the potential for expansion beyond the initial programme.

Singh said: “This agreement represents strong, high-quality validation of our proprietary capabilities from a leading industry partner, and we are confident that this relationship will expand across other areas of the Customer’s research and development portfolio.”

He added that the company’s integrated analytical suite is designed to address complexity in multimodal biological datasets and support decision-making in drug target discovery.

The BullFrog AI platform combines causal network inference with machine learning tools designed to interpret large-scale biological and clinical datasets. The company said this approach is intended to help researchers better understand disease mechanisms and prioritise therapeutic targets more efficiently than conventional methods.

The commercial agreement centres on applying these capabilities to major depressive disorder, a large and growing global mental health condition and a leading cause of disability worldwide. The company referenced industry estimates suggesting the market could exceed $11bn by 2032, driven by steady annual growth.

The collaboration reflects wider industry interest in artificial intelligence tools that can be applied to early-stage drug development, particularly in complex neurological and psychiatric conditions where traditional target discovery has proven challenging.

BullFrog AI said its broader strategy is focused on expanding partnerships with pharmaceutical and academic collaborators to apply its platform across multiple therapeutic areas, with an emphasis on improving efficiency in drug discovery pipelines and reducing late-stage attrition.

Additional details of the agreement will be disclosed in a regulatory filing.